INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 159 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2017. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $735 | +293.0% | 54,751 | +261.1% | 0.07% | +257.9% |
| Q4 2022 | $187 | -99.9% | 15,163 | +208.3% | 0.02% | -68.3% |
| Q1 2020 | $310,000 | +30.8% | 4,918 | +108.5% | 0.06% | +46.3% |
| Q4 2018 | $237,000 | -71.2% | 2,359 | -65.3% | 0.04% | -73.7% |
| Q2 2017 | $824,000 | +99.0% | 6,798 | +85.6% | 0.16% | +60.8% |
| Q1 2017 | $414,000 | – | 3,662 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
| Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
| DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
| GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
| BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
| Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
| ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
| Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
| QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
| Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |